Fig. 2From: Advantages of the net benefit regression framework for trial-based economic evaluations of cancer treatments: an example from the Canadian Cancer Trials Group CO.17 trialProbability that new treatment is cost-effective for KRAS-WT (upper solid line), all patients (middle dashed line) and KRAS-MUT (lower hashed line) by Willingness to Pay threshold valuesBack to article page